AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Trial Details

NCT ID
NCT07454642
Phase
PHASE1
Sponsor
Avacta Life Sciences Ltd
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • AVA6103
Locations (sample)
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Irving, Texas, United States|32.81402,-96.94889
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • The subject is fully informed about the study and is willing and able to sign the informed consent form (ICF).
  • Male or female subjects, ≥18 years of age.
  • Subjects with the following tumors reported to be FAP positive, with histological or cytological confirmation of a locally advanced (unresectable) …
  • Cervical/vulvar cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →